CVS Health (CVS) recently saw a 1.15% daily stock decline, underperforming a rising market, though its shares have gained 7.37% over the past month, outpacing the Medical sector and S&P 500. The company is set to report earnings on October 29, 2025, with consensus estimates forecasting a 24.77% year-over-year EPS growth to $1.36 and a 3% revenue increase to $98.29 billion for the quarter. Analysts maintain a positive outlook, assigning a Zacks Rank of #2 (Buy), supported by valuation metrics like a Forward P/E of 12.89 and a PEG ratio of 0.9, both trading at a discount to industry averages.
CVS Health (CVS) closed at $81.07, down 1.15%, underperforming the S&P 500's 0.58% gain in the latest session. Despite this, the stock has climbed 7.37% over the past month, significantly outpacing the Medical sector's 3.7% and the S&P 500's 0.16% gains, indicating strong recent momentum. The company's upcoming earnings report on October 29, 2025, is a key event. Consensus estimates project a robust 24.77% year-over-year EPS growth to $1.36 and a 3% revenue increase to $98.29 billion for the quarter, alongside strong annual forecasts. Analyst sentiment is bullish, reflected by a Zacks Rank of #2 (Buy) and a 0.03% upward revision in the Zacks Consensus EPS estimate. Valuation metrics appear attractive, with CVS trading at a Forward P/E of 12.89, a discount to its industry average of 17.11, and a favorable PEG ratio of 0.9 versus the industry's 1.72. CVS operates within the Medical Services industry, holding a strong Zacks Industry Rank of 95, placing it in the top 39% of all industries. This strong industry positioning, combined with positive fundamental outlook and attractive valuation, supports a favorable investment thesis.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.65
Ticker Sentiment
